Lane Frey, MD
Endocrinology, Diabetes & Metabolism · Thibodaux, LANPI 1932337052
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $177,537 of the $201,859 with a category attached, or 88.0%. Novo Nordisk accounts for 81.9% of it on its own, with 37 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 574 payments — averaging $351.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$165K
- Boehringer Ingelheim$24K
- Lilly USA, LLC$8K
- AstraZeneca$445
- Amgen$392
- Sanofi-aventis U.S. LLC$346
- plus $3K from 32 others
What the payments were for
- Consulting fees$2,9251%
- Speaking & faculty fees$177,53788%
- Travel & lodging$10,5975%
- Food & beverage$10,7095%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 266 | $165,321 |
| Boehringer Ingelheim | 57 | $24,194 |
| Lilly USA, LLC | 51 | $8,388 |
| AstraZeneca | 15 | $445 |
| Amgen(2 entities) | 18 | $392 |
| Sanofi-aventis U.S. LLC | 19 | $346 |
| Abbott | 18 | $342 |
| Dexcom, Inc. | 12 | $234 |
| Xeris Pharmaceuticals, Inc. | 12 | $225 |
| Corcept Therapeutics | 8 | $169 |
| Bayer | 8 | $155 |
| AbbVie | 10 | $153 |
| IBSA Pharma Inc. | 7 | $131 |
| Antares Pharma, Inc. | 7 | $126 |
| Medtronic(2 entities) | 7 | $122 |
| Tandem Diabetes Care, Inc. | 5 | $113 |
| Insulet Corporation | 5 | $106 |
| BETA Bionics, Inc. | 5 | $106 |
| Tolmar, Inc. | 4 | $86 |
| Amneal Pharmaceuticals LLC | 5 | $84 |
| Merck | 5 | $79 |
| Novartis | 3 | $59 |
| Amarin Pharma, Inc. | 3 | $53 |
| Recordati_rare_diseases_inc. | 3 | $51 |
| Nevro Corp. | 3 | $47 |
| Ascendis Pharma Endocrinology Inc | 2 | $45 |
| Johnson & Johnson | 3 | $43 |
| BD | 2 | $41 |
| Shire North American Group Inc | 2 | $40 |
| Sequel Med Tech, LLC | 1 | $25 |
| Cequr Corporation | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Halozyme Inc | 1 | $17 |
| Valeritas, Inc. | 1 | $15 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Lifescan, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$201,859 in reported general payments places this provider in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,296 | $2,316,186 |
| JardianceEmpagliflozin | 1,280 | $1,419,438 |
| TrulicityDulaglutide | 472 | $798,037 |
| MounjaroTirzepatide | 399 | $771,733 |
| Tresiba Flextouch U-200Insulin Degludec | 397 | $377,810 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 313 | $357,857 |
| FarxigaDapagliflozin Propanediol | 343 | $336,374 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 174 | $169,232 |
| KerendiaFinerenone | 145 | $159,519 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 84 | $138,217 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 155 | $123,007 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $93,555 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 34 | $82,371 |
| Novolog FlexpenInsulin Aspart | 215 | $64,110 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 51 | $61,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $165,321 | $2,503,2541,435 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Baqsimi | $8,388 | $1,576,531884 claims |
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Glyxambi | $24,194 | $1,473,4271,326 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $346 | $357,857313 claims |
| AstraZenecaFarxiga | $445 | $336,374343 claims |
| BayerKerendia | $155 | $159,519145 claims |
| MerckJanuvia | $79 | $53,67460 claims |
| Johnson & JohnsonInvokana | $43 | $29,66030 claims |
| AbbVieSynthroid | $153 | $28,461363 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $84 | $17,6931,719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Thibodaux
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
- Harold MillerHammond$73K
- Tilak MallikMarrero$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.